| 摘要 |
This invention relates to combinations of an auristatin or an auristatin-based antibody-drug-conjugate (ADC) with second active agents including PI3K/mTOR inhibitors, MEK inhibitors, taxanes, or other anti-cancer agents, and methods of treating abnormal cell growth by administering these combinations to patients. |
